Media headlines about Fresenius Medical Care AG & Co. (NYSE:FMS) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Fresenius Medical Care AG & Co. earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave news articles about the company an impact score of 44.9457055353522 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Shares of Fresenius Medical Care AG & Co. (NYSE FMS) traded down $1.14 during trading hours on Tuesday, reaching $53.47. 169,463 shares of the company were exchanged, compared to its average volume of 142,661. The stock has a market cap of $33,470.69, a PE ratio of 23.98, a PEG ratio of 2.08 and a beta of 0.52. Fresenius Medical Care AG & Co. has a one year low of $40.60 and a one year high of $57.94. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.98 and a current ratio of 1.22.
A number of equities analysts recently commented on the stock. Zacks Investment Research upgraded shares of Fresenius Medical Care AG & Co. from a “hold” rating to a “buy” rating and set a $62.00 target price on the stock in a research report on Thursday, January 18th. Nord/LB reiterated a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research report on Wednesday, December 27th. SunTrust Banks set a $62.00 target price on shares of Fresenius Medical Care AG & Co. and gave the stock a “buy” rating in a research report on Thursday, December 21st. DZ Bank reiterated a “buy” rating on shares of Fresenius Medical Care AG & Co. in a research report on Monday, November 13th. Finally, Morgan Stanley cut shares of Fresenius Medical Care AG & Co. from an “overweight” rating to an “equal weight” rating in a research report on Monday, December 11th. Six research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $56.00.
Fresenius Medical Care AG & Co. Company Profile
Fresenius Medical Care AG & Co KGaA is a kidney dialysis company. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company’s segments include North America Segment, the Europe, Middle East and Africa (EMEA) Segment, the Asia-Pacific Segment and the Latin America Segment.
Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.